Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityNon-Current AssetsOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Inhibikase Therapeutics (IKT) Short-term Investments (2022 - 2026)

Inhibikase Therapeutics (IKT) has 5 years of Short-term Investments data on record, last reported at $120.8 million in Q1 2026.

  • On a quarterly basis, Short-term Investments rose 511.97% to $120.8 million in Q1 2026 year-over-year; TTM through Mar 2026 was $120.8 million, a 511.97% increase, with the full-year FY2025 number at $39.5 million, down 3.68% from a year prior.
  • Short-term Investments reached $120.8 million in Q1 2026 per IKT's latest filing, up from $39.5 million in the prior quarter.
  • Over the last five years, Short-term Investments for IKT hit a ceiling of $120.8 million in Q1 2026 and a floor of $2.0 million in Q3 2023.
  • A 5-year average of $24.5 million and a median of $19.0 million in 2023 define the central range for Short-term Investments.
  • Peak YoY movement for Short-term Investments: plummeted 90.51% in 2023, then skyrocketed 1575.91% in 2025.
  • Tracing IKT's Short-term Investments over 5 years: stood at $15.9 million in 2022, then plummeted by 74.23% to $4.1 million in 2023, then surged by 904.51% to $41.1 million in 2024, then fell by 3.68% to $39.5 million in 2025, then surged by 205.47% to $120.8 million in 2026.
  • Business Quant data shows Short-term Investments for IKT at $120.8 million in Q1 2026, $39.5 million in Q4 2025, and $39.1 million in Q3 2025.